Analytical and Clinical Validation of a Rapid FDA-Approved NGS Solution for Companion Diagnostics and Tumor Profiling: Performance, Workflow, and Turnaround Time

Next-generation sequencing (NGS) has become essential for precision oncology, yet implementation challenges such as workflow complexity, limited laboratory resources, and prolonged turnaround times can delay actionable results. The FDA-approved Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer was developed to address these barriers through a highly automated, rapid NGS workflow that enables both companion diagnostics and comprehensive tumor profiling. This presentation will review the analytical and clinical validation of the assay, including performance characteristics, workflow efficiency, and operational considerations for decentralized clinical laboratories. The session will highlight the test’s ability to deliver clinically actionable genomic insights from minimal sample input with results in as little as 24 hours, supporting timely treatment in oncology care. Real-world implementation considerations and the role of rapid NGS in expanding access to precision medicine will also be discussed.